SEARCH

SEARCH BY CITATION

References

  • 1
    Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43: 32939.
  • 2
    Cuffari C, Theoret Y, Lotour S, Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996; 39: 4016.
  • 3
    Dubinski M, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 70513.
  • 4
    Cuffari C, Hunt S, Bayless T. Utilization of erythrocyte 6-thioguanine metabolite levels to optimize azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 6426.
  • 5
    Achkar JP, Stevens T, Easely K, et al. Indicators of clinical response to treatment with 6-mercaptopurine in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 33945.
  • 6
    Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49: 66570.
  • 7
    Gupta P, Gokhale R, Kirschner B. 6-Mercaptopurine levels in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 33: 4504.
  • 8
    Belaiche J, Desager JP, Horsmans Y, et al. Therapeutic monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn's disease. Scand J Gastroenterol 2001; 36: 716.
  • 9
    Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease: a meta-analysis. Ann Intern Med 1995; 122: 13242.
  • 10
    Cuffari C, Hunt S, Bayless M. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol Ther 2000; 14: 100914.
  • 11
    Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995; 39: 4569.
  • 12
    Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001; 49: 65664.
  • 13
    Sandborn WJ, Tremain WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. Gastroenterology 1999; 117: 52735.
  • 14
    Zimm S, Collinis JM, Riccardi R, et al. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 1983; 308: 10059.
  • 15
    Arndt CAS, Balis FM, McCully CL, et al. Bioavailability of low-dose vs. high-dose 6-mercaptopurine. Clin Pharmacol Ther 1988; 43: 58891.
  • 16
    Burton NK, Barnett MJ, Aherne GW, Evans J, Douglas I, Lister TA. The effect of food on the oral administration of 6-mercaptopurine. Cancer Chemother Pharmacol 1986; 18: 901.
  • 17
    Ding TL, Benet LZ. Comparative bioavailability and pharmacokinetic study of azathioprine and 6-mercaptopurine in rhesus monkey. Drug Metab Dispos 1979; 7: 3737.
  • 18
    Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126: 60814.
  • 19
    Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenetic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 65162.
  • 20
    Lennard L, Van Loon JA, Lilleyman JS, et al. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 1987; 41: 1825.
  • 21
    Lewis LD, Benin A, Szumlanski CL, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 1997; 62: 46475.
  • 22
    Markowitz JF, Daum F. Inhibiting thiopurine methyltransferase activity with mesalamine improves therapeutic mercaptopurine metabolites in children with Crohn's disease. Am J Gastroenterol 2000; 95: 2542.
    Direct Link: